Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 0.69 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MPO | P05164 | 5/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | HTR1D | P28221 | 2/20 | 0.50 |
| ▸ | HTR1B | P28222 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7823519 | 0.98 | HTR2A (0.97) | HTR2AHTR6TRPM8LTA4HPLA2G2A | |
| SCHEMBL14907351 | 0.85 | HTR2A (0.74) | HTR2AHTR6TRPM8LTA4HPLA2G2A | |
| SCHEMBL23707172 | 0.82 | HTR2A (0.69) | HTR2AHTR6TRPM8LTA4HPLA2G2A | |
| SCHEMBL27085094 | 0.82 | HTR6 (1.00) | HTR2AHTR6MPOSLC6A4MTNR1A | |
| SCHEMBL30630326 | 0.82 | HTR6 (1.00) | HTR2AHTR6MPOSLC6A4MTNR1A | |
| SCHEMBL24328225 | 0.81 | HTR2A (0.68) | HTR2AHTR6TRPM8LTA4HPLA2G2A | |
| SCHEMBL14962766 | 0.81 | HTR2A (0.68) | HTR2AHTR6TRPM8LTA4HPLA2G2A | |
| SCHEMBL21333087 | 0.81 | HTR2A (0.68) | HTR2AHTR6TRPM8LTA4HPLA2G2A | |
| SCHEMBL5791794 | 0.81 | HTR2A (0.68) | HTR2AHTR6TRPM8LTA4HPLA2G2A | |
| SCHEMBL1399218 | 0.80 | HTR2A (0.66) | HTR2AHTR6TRPM8LTA4HPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535403-A | Beta-carbopol derivative and preparation method, pharmaceutical composition and application thereof | 沈阳药科大学 | 2023-08-04 | — | — | CN | claimed |
| CN-115850269-A | Tetrahydro-beta-carboline compound and preparation method and application thereof | 南京工业大学 | 2023-03-28 | — | — | CN | claimed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| CN-1938018-A | Use of compounds capable of increasing serum IGF-1 levels for the preparation of therapeutic compositions for the treatment of various disease states associated with decreased IGF-1 serum levels in humans and animals | VEIJLEN LTD (AN) | 2007-03-28 | — | — | CN | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| CN-116535403-B | Beta-carbopol derivative and preparation method, pharmaceutical composition and application thereof | 沈阳药科大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-115536638-B | Triazole compound and application thereof | 上海交通大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-116535403-A | Beta-carbopol derivative and preparation method, pharmaceutical composition and application thereof | 沈阳药科大学 | 2023-08-04 | — | — | CN | disclosed |
| EP-0620222-A2 | Tetrahydro-beta-carbolines | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| US-4414220-A | HUPOGLYCEMIC, ANTIDIABETIC | PFIZER INC. (US) | 1983-11-08 | — | — | US | disclosed |
| US-4333932-A | DIHYDROISOINDOLES, HYPOGLYCEMIC, ANTIDIABETIC | PFIZER INC. (US) | 1982-06-08 | — | — | US | disclosed |
| EP-0010896-B1 | ORGANIC DIAMINE COMPOUNDS FOR USE AS ORAL HYPOGLYCEMIC AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4220650-A | HYPOGLYCEMIC | PFIZER INC. (US) | 1980-09-02 | — | — | US | disclosed |
| EP-0010896-A1 | Organic diamine compounds for use as oral hypoglycemic agents and pharmaceutical compositions thereof | PFIZER INC. (US) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | HTR2A 115/4885HTR6 153/4885TRPM8 451/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | HTR2A 115/4885HTR6 153/4885TRPM8 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.